RB1 and neoplasm: In over 90% of lung cancers, the cell cycle occurs as dysregulation, which makes the derangements of cell cycle mediators in the expression and/or activation, especially within the CDK–cyclin–RB pathways, and is integrally involved in malignant transformation and tumor progression, destroying the cell proliferation mechanism controlling the growth of advanced NSCLC (3–5).